Azyter: first macrolide preparation for ocular use

Azyter eye drops are preservative-free.
Azyter eye drops are preservative-free.

Azithromycin is now available as eye drops for the treatment of purulent bacterial or trachomatous conjunctivitis. Azyter (azithromycin) is presented in single-dose units containing 15mg/g of the active ingredient. Administered twice daily for 3 days, it has a shorter dose regimen than many other ophthalmic anti-infectives. As a macrolide, azithromycin has a broad spectrum of activity. It is effective against the majority of bacteria responsible for common eye infections, including Gram-positive cocci (eg, Staphylococcus aureus), Gram-negative species (eg, Haemophilus influenzae) and intracellular pathogens (eg, Chlamydia trachomatis).

In a randomised, double-blind study in 670 children aged 1–10 years with conjunctivitis caused by Chlamydia trachomatis, the 60-day clinical cure rate achieved with azithromycin eye drops was non-inferior to that achieved with an oral azithromycin dose (96.3% vs 96.6%).

Azithromycin eye drops were also evaluated in a randomised, investigator-blinded study in adults and children with purulent bacterial conjunctivitis. Participants received azithromycin drops twice daily for 3 days or tobramycin 0.3% drops every 2 hours for 2 days then 4 times daily for 5 days. The clinical cure rate for azithromycin at day 9 in the per-protocol analysis (n=471) was non-inferior to that of tobramycin (87.8% vs 89.4%), with a similar microbiological resolution rate.

View Azyter drug record

Further Information: Spectrum Thea Pharma

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases